A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant
The risk associated with bloodless autologous hematopoietic cell transplantation (aHCT) includes severe bleeding and profound anemia. Support with platelet (PLT) or RBC transfusions is often required to prevent complications associated with temporary marrow aplasia before hematopoietic recovery. Without transfusion support, profound anemia may lead to decreased systemic perfusion and cause multiorgan failure. Similarly, profuse bleeding occurring during severe thrombocytopenia may be detrimental.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Jennifer C. Zhao, Justin R. Arnall, Allison L. Martin, Shebli Atrash, Manisha Bhutani, Peter Voorhees, Belinda Avalos, Edward Copelan, Nilanjan Ghosh, Mehdi Hamadani, Saad Usmani, Patricia Ford Source Type: research
More News: Anemia | Biology | Bleeding | Hematology | Perfusion | Stem Cell Therapy | Stem Cells | Thrombocytopenia | Transplants